Advised Arcline Investment Management in the acquisition of the Valencian biotech company Polypeptide Therapeutic Solutions (PTS) from Columbus Venture Partners.
Cuatrecasas lawyers advised private equity firm Arcline Investment Management on buying Valencian biotechnology company Polypeptide Therapeutic Solutions (PTS) from Columbus Venture Partners. This is the first transaction in Spain by the US firm, which manages $4.3 billion and is growth-oriented in sectors such as defense and medical technology.
This acquisition will allow PTS to continue to improve its groundbreaking formula for the large-scale production of polymers at an accessible cost. Thanks to these advances, administering drugs and medications is more effective, safe and precise through drug encapsulation solutions. Arcline will also enable PTS to export its technology to more countries in Europe and North America.
The Cuatrecasas advisory team included lawyers from the Corporate and Commercial Practice Antonio Baena, Diego Pérez-Yarza, Sara Shackleford, Sergio Ochagavía, Olga Corbal, Soraya Sáenz de Santamaría and Jesús García, with strong support from the firm’s Competition, Tax, Labor and Employment, and Intellectual Property Practices.